Viking Therapeutics Inc. (VKTX)
Viking Therapeutics: Potential Winner In Competitive Obesity Drug Race
Eli Lilly and Novo Nordisk dominate a weight loss drug sector heading towards a competitive race, but the market opportunity could reach over $100 billion. Viking Therapeutics, Inc. shows promising results with VK2735, potentially outperforming competitors in weight loss trials. The stock is an attractive investment with the potential for a premium buyout and consensus analyst price targets over 100% higher.
Viking (VKTX) Skyrockets 197% YTD: Is the Stock Worth a Buy?
Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.
Viking Therapeutics Stock Is Up by 154% Since January -- Can It Double Again in the Second Half of the Year?
Viking Therapeutics stock is flying high thanks to its two leading pipeline candidates. But the biotech doesn't have any expected major catalysts to jolt its price by year-end.
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $47.39, denoting a -0.86% change from the preceding trading day.
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $50.43, marking a -0.41% move from the previous day.
The Best Biotech Stock to Invest $1,000 in Right Now
Viking Therapeutics has a few promising drug programs near maturity. It will have to ward off tough competitors to succeed.
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It
Viking Therapeutics has the potential to be a great growth stock. The company, however, faces a lot of competition in the GLP-1 drug market.
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $52.10, denoting a -0.69% change from the preceding trading day.
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
This High-Flying Stock Just Announced More Good News: Time to Buy?
Viking Therapeutics just reported (more) positive phase 2 clinical trial results. Though the company's shares dropped, interested investors shouldn't worry.
Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $55.99, signifying a +1.78% move from its prior day's close.
Is Viking Therapeutics Stock a Buy on the Dip?
Viking Therapeutics stock took a hit this week in response to a clinical update for its midstage liver disease drug. This pullback seems unwarranted, given the company's pivot to weight loss.
